SI21122A - Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku - Google Patents

Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku Download PDF

Info

Publication number: SI21122A
Authority: SI; Slovenia
Prior art keywords: strains; preparation; parapoxvirus; dependent; diseases
Prior art date: 2000-07-11

Application number

SI200120048A

Other languages

English (en)

Slovenian (sl)

Inventor

Olaf Weber

Tobias Schlapp

Angela Siegling

Andreas Knorr

Claudia Hirth-Dietrich

Gudrun Theiss

Original Assignee

Bayer Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-11

Filing date

2001-07-11

Publication date

2003-08-31

2001-05-09 Priority claimed from DE10122451A external-priority patent/DE10122451A1/de

2001-07-11 Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft

2003-08-31 Publication of SI21122A publication Critical patent/SI21122A/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Hematology (AREA)
Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Diabetes (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SI200120048A 2000-07-11 2001-07-11 Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku SI21122A (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10033582		2000-07-11
DE10122451A DE10122451A1 (de)	2000-07-11	2001-05-09	Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
PCT/EP2001/007991 WO2002004002A2 (de)	2000-07-11	2001-07-11	Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs

Publications (1)

Publication Number	Publication Date
SI21122A true SI21122A (sl)	2003-08-31

Family

ID=26006335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200120048A SI21122A (sl)	2000-07-11	2001-07-11	Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku

Country Status (36)

Country	Link
US (1)	US6685950B2 (lt)
EP (1)	EP1303286B1 (lt)
JP (1)	JP5037775B2 (lt)
CN (1)	CN1455674B (lt)
AR (1)	AR029954A1 (lt)
AT (1)	ATE324115T1 (lt)
AU (2)	AU7063101A (lt)
BG (1)	BG107448A (lt)
CA (1)	CA2415397C (lt)
CY (1)	CY1105408T1 (lt)
CZ (1)	CZ200371A3 (lt)
DE (1)	DE50109630D1 (lt)
DK (2)	DK1303286T3 (lt)
EE (1)	EE200300018A (lt)
ES (1)	ES2262663T3 (lt)
FI (1)	FI20030037A7 (lt)
GB (1)	GB2381454B8 (lt)
HK (1)	HK1054329B (lt)
HR (1)	HRP20030096A2 (lt)
HU (1)	HUP0400479A3 (lt)
IL (1)	IL153643A0 (lt)
LT (1)	LT5079B (lt)
LU (1)	LU90997B1 (lt)
LV (1)	LV12990B (lt)
MA (1)	MA26927A1 (lt)
MX (1)	MXPA03000279A (lt)
NO (1)	NO20030082L (lt)
NZ (1)	NZ523534A (lt)
PL (1)	PL366397A1 (lt)
PT (1)	PT1303286E (lt)
RU (1)	RU2003104525A (lt)
SE (1)	SE0300034L (lt)
SI (1)	SI21122A (lt)
SK (1)	SK362003A3 (lt)
UY (1)	UY26832A1 (lt)
WO (1)	WO2002004002A2 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19922407A1 (de) *	1999-05-14	2000-11-16	Bayer Ag	Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
CN101676389A (zh) *	2000-11-23	2010-03-24	巴法里安诺迪克有限公司	改良安卡拉痘苗病毒变体
US7628980B2 (en) *	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) *	2000-11-23	2006-08-29	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
NZ512341A (en) *	2001-06-13	2004-02-27	Bayer Ag	Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
WO2003049683A2 (en)	2001-12-07	2003-06-19	Bayer Pharmacueticals Corporation	Use of parapox b2l protein to treat cancer and modify immune responses
PL220781B1 (pl) *	2002-04-19	2016-01-29	Bavarian Nordic As	Zastosowanie wirusa krowianki Ankara (MVA) szczepu MVA-BN
DK1434858T4 (en) *	2002-09-05	2019-04-01	Bavarian Nordic As	PROCEDURE FOR AMPLIFICATION OF A POXVIRUS UNDER SERUM-FREE CONDITIONS
DK1765370T3 (da) *	2004-07-13	2009-11-02	Aicuris Gmbh & Co Kg	Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
JP5164849B2 (ja) *	2005-11-24	2013-03-21	アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト	癌の処置用の生物化学療法としての古典的細胞傷害性化学療法剤と組み合わせたパラポックスウイルス
JP5004990B2 (ja) *	2009-03-31	2012-08-22	アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト	パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
WO2011072871A1 (en) *	2009-12-18	2011-06-23	Bavarian Nordic A/S	Production of ifn-lambda by conventional dendritic cells and uses thereof
JP5699093B2 (ja) *	2012-01-05	2015-04-08	アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓＧｍｂＨ＆Ｃｏ．ＫＧ	パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) *	2017-09-07	2019-06-01	德商艾庫瑞斯公司	使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083950A1 (en) *	2021-11-10	2023-05-19	Aicuris Gmbh & Co. Kg	Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2023083943A1 (en) *	2021-11-10	2023-05-19	Aicuris Gmbh & Co. Kg	Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2714665A1 (de) *	1977-04-01	1978-10-05	Mayr Anton	Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE3504940C2 (de) *	1984-02-17	1997-11-06	Bayer Ag	Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
US5443964A (en) *	1987-08-10	1995-08-22	Duke University	Poxvirus insertion/expression vector
DE4405841C1 (de) *	1994-02-23	1995-01-05	Mayr Anton Prof Dr Med Vet Dr	Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) *	1994-11-14	1997-07-15	Tawashi; Rashad	Drug delivery of nitric oxide
WO1997032029A1 (de) *	1996-02-28	1997-09-04	Bayer Aktiengesellschaft	Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
CN1217751A (zh) *	1996-03-29	1999-05-26	奥塔戈大学	副痘病毒载体
JP3568208B2 (ja) *	1996-04-15	2004-09-22	マイヤー，アントン	弱毒化された非免疫原性ポックスウイルスまたはパラポックスウイルスからの多種有効性パラポックス免疫誘導剤の薬剤としての使用のための新規薬効
SE9700617D0 (sv) *	1997-02-21	1997-02-21	Kjell Alving	New composition
DE19843222A1 (de) *	1998-09-22	2000-03-30	Hassan Jomaa	Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
DE69931178T8 (de) *	1998-11-02	2007-06-28	Ludwig Institute For Cancer Research	Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

2001
- 2001-07-11 SK SK36-2003A patent/SK362003A3/sk not_active Application Discontinuation
- 2001-07-11 PL PL01366397A patent/PL366397A1/xx not_active Application Discontinuation
- 2001-07-11 EP EP01949489A patent/EP1303286B1/de not_active Expired - Lifetime
- 2001-07-11 AT AT01949489T patent/ATE324115T1/de active
- 2001-07-11 IL IL15364301A patent/IL153643A0/xx active IP Right Grant
- 2001-07-11 GB GB0302630A patent/GB2381454B8/en not_active Expired - Fee Related
- 2001-07-11 NZ NZ523534A patent/NZ523534A/en not_active IP Right Cessation
- 2001-07-11 AU AU7063101A patent/AU7063101A/xx active Pending
- 2001-07-11 FI FI20030037A patent/FI20030037A7/fi not_active IP Right Cessation
- 2001-07-11 EE EEP200300018A patent/EE200300018A/xx unknown
- 2001-07-11 SI SI200120048A patent/SI21122A/sl not_active IP Right Cessation
- 2001-07-11 HR HR20030096A patent/HRP20030096A2/xx not_active Application Discontinuation
- 2001-07-11 LU LU90997A patent/LU90997B1/en active
- 2001-07-11 JP JP2002508456A patent/JP5037775B2/ja not_active Expired - Lifetime
- 2001-07-11 AR ARP010103292A patent/AR029954A1/es unknown
- 2001-07-11 HK HK03106613.1A patent/HK1054329B/zh not_active IP Right Cessation
- 2001-07-11 RU RU2003104525/15A patent/RU2003104525A/ru not_active Application Discontinuation
- 2001-07-11 HU HU0400479A patent/HUP0400479A3/hu unknown
- 2001-07-11 US US09/903,013 patent/US6685950B2/en not_active Expired - Lifetime
- 2001-07-11 WO PCT/EP2001/007991 patent/WO2002004002A2/de not_active Ceased
- 2001-07-11 AU AU2001270631A patent/AU2001270631B2/en not_active Expired - Fee Related
- 2001-07-11 ES ES01949489T patent/ES2262663T3/es not_active Expired - Lifetime
- 2001-07-11 PT PT01949489T patent/PT1303286E/pt unknown
- 2001-07-11 UY UY26832A patent/UY26832A1/es not_active Application Discontinuation
- 2001-07-11 DE DE50109630T patent/DE50109630D1/de not_active Expired - Lifetime
- 2001-07-11 CN CN01812685.5A patent/CN1455674B/zh not_active Expired - Lifetime
- 2001-07-11 CZ CZ200371A patent/CZ200371A3/cs unknown
- 2001-07-11 MX MXPA03000279A patent/MXPA03000279A/es unknown
- 2001-07-11 DK DK01949489T patent/DK1303286T3/da active
- 2001-07-11 CA CA2415397A patent/CA2415397C/en not_active Expired - Lifetime
2003
- 2003-01-08 BG BG107448A patent/BG107448A/bg unknown
- 2003-01-08 NO NO20030082A patent/NO20030082L/no unknown
- 2003-01-10 MA MA26994A patent/MA26927A1/fr unknown
- 2003-01-10 SE SE0300034A patent/SE0300034L/xx not_active Application Discontinuation
- 2003-01-10 DK DK200300015A patent/DK200300015A/da not_active Application Discontinuation
- 2003-02-03 LT LT2003009A patent/LT5079B/lt not_active IP Right Cessation
- 2003-02-11 LV LVP-03-14A patent/LV12990B/lv unknown
2006
- 2006-07-24 CY CY20061101024T patent/CY1105408T1/el unknown

Also Published As

Publication number	Publication date
IL153643A0 (en)	2003-07-06
HK1054329A1 (en)	2003-11-28
DK200300015A (da)	2003-03-07
CN1455674B (zh)	2019-03-29
LT5079B (lt)	2003-12-29
SE0300034L (sv)	2003-03-03
JP5037775B2 (ja)	2012-10-03
FI20030037L (fi)	2003-03-10
NZ523534A (en)	2005-02-25
GB2381454A (en)	2003-05-07
GB2381454A8 (en)	2007-10-23
UY26832A1 (es)	2002-01-31
WO2002004002A3 (de)	2002-10-31
MA26927A1 (fr)	2004-12-20
JP2004517807A (ja)	2004-06-17
DK1303286T3 (da)	2006-08-28
AR029954A1 (es)	2003-07-23
HUP0400479A2 (hu)	2004-06-28
SE0300034D0 (sv)	2003-01-10
ATE324115T1 (de)	2006-05-15
HRP20030096A2 (en)	2005-02-28
CA2415397C (en)	2011-04-26
WO2002004002A2 (de)	2002-01-17
SK362003A3 (en)	2003-07-01
CA2415397A1 (en)	2002-01-17
NO20030082D0 (no)	2003-01-08
CN1455674A (zh)	2003-11-12
LT2003009A (lt)	2003-08-25
US20030021769A1 (en)	2003-01-30
GB2381454B8 (en)	2007-10-23
LV12990B (en)	2003-08-20
RU2003104525A (ru)	2004-06-27
FI20030037A7 (fi)	2003-03-10
AU7063101A (en)	2002-01-21
HK1054329B (zh)	2005-10-07
US6685950B2 (en)	2004-02-03
PT1303286E (pt)	2006-08-31
CY1105408T1 (el)	2010-04-28
CZ200371A3 (cs)	2003-04-16
DE50109630D1 (de)	2006-06-01
EP1303286A2 (de)	2003-04-23
ES2262663T3 (es)	2006-12-01
EP1303286B1 (de)	2006-04-26
PL366397A1 (pl)	2005-01-24
GB0302630D0 (en)	2003-03-12
BG107448A (bg)	2003-11-28
MXPA03000279A (es)	2004-04-05
EE200300018A (et)	2004-10-15
AU2001270631B2 (en)	2005-07-07
HUP0400479A3 (en)	2006-02-28
NO20030082L (no)	2003-01-08
LU90997B1 (en)	2003-01-08
GB2381454B (en)	2004-11-24

Publication	Publication Date	Title
SI21122A (sl)	2003-08-31	Uporaba sevov parapoksvirusa ovis za proizvodnjo antivirusnih zdravil in zdravil proti raku
CN111588721B (zh)	2021-06-08	化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途
CN115040511A (zh)	2022-09-13	Esi-09在防治gcrv感染中的应用
CN115197231B (zh)	2023-01-17	广谱抗病毒中药单体小檗胺及其应用
CN111714621A (zh)	2020-09-29	转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
WO2013189003A1 (zh)	2013-12-27	J亚群禽白血病病毒的肽核酸及其应用
JP2012121902A (ja)	2012-06-28	抗ウイルス薬および癌に対する医薬を製造するためのパラポックスウイルスｏｖｉｓ株の使用
EP1991254A2 (en)	2008-11-19	Broad spectrum immune and antiviral gene modulation by oral interferon
EP1951274B1 (en)	2009-12-02	Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
CN118127004A (zh)	2024-06-04	靶向HSV必需基因的gRNA、CRISPR/Cas基因编辑系统、递送系统及应用
JP2000007578A (ja)	2000-01-11	Ｃ型肝炎ウイルスの陰性化のための投薬システム
WO2022033469A1 (zh)	2022-02-17	重组溶瘤病毒及其构建方法和用途
CN101979556B (zh)	2015-01-21	一种siRNA靶向分子及其应用
HK1060063A (en)	2004-07-30	Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
CN106581052B (zh)	2020-11-06	柠檬酸根离子和铁离子在抑制rna病毒中的应用
CN112691094B (zh)	2022-09-23	防治病毒的新型化合物及其应用
WO2024113302A1 (zh)	2024-06-06	靶向HSV必需基因的gRNA、CRISPR/Cas基因编辑系统、递送系统及应用
CN116870134A (zh)	2023-10-13	θ-防御素在制备抗猫杯状病毒感染药物中的应用
AU9743098A (en)	1999-04-05	Use of ifn-alpha and amantadine for the treatment of chronic hepatitis C
CN118078824A (zh)	2024-05-28	抗马立克氏病病毒的药物以及ra190或甘草酸及其联合使用在药物制备中的应用
Martino et al.	2000	Treatment of Hepatic Abcesses in Chronic Granulomatous Disease with Granulomatous Disease with...
Underwood et al.	0	Ganciclovir (GCV) resistance due to a new mutation in the

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date
2007-04-30	KO00	Lapse of patent	Effective date: 20070226